Rhelion confirms further PEX010 delivery to Germany compassionate use program
Rhelion Life Sciences said it has confirmed further delivery of Filament Health's PEX010 to Germany’s First Psilocybin Compassionate Use Program.
Toronto, Ontario--(. - September 3, 2026) - Rhelion Life Sciences Corp.
CSE:RHEL (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned su…